Intelligent Gene Delivery Systems
Legal Citation
Summary of the Inventive Concept
This inventive concept integrates self-replicating cell selective gene delivery compositions with advanced technologies like AI, IoT, blockchain, and machine learning to create a more powerful and efficient gene delivery system.
Background and Problem Solved
Despite the progress in gene therapy, targeted gene delivery remains a significant challenge. The original patent's self-replicating cell selective gene delivery compositions have limitations in terms of tracking, optimization, and personalization. This new inventive concept addresses these limitations by combining the patented technology with synergistic technologies to create a more effective and efficient gene delivery system.
Detailed Description of the Inventive Concept
The new system comprises a self-replicating cell selective gene delivery composition, a blockchain-based tracking module, and a machine learning algorithm for optimizing gene delivery routes. The blockchain module enables secure, transparent, and tamper-proof tracking of gene expression and patient data, while the machine learning algorithm identifies the most effective gene delivery routes. Additionally, the system can be integrated with IoT-enabled bioreactors for customized composition generation and AI-powered genomic analysis for personalized gene therapy.
Novelty and Inventive Step
The new claims introduce the synergistic combination of self-replicating cell selective gene delivery compositions with advanced technologies like AI, IoT, blockchain, and machine learning, which is not obvious from the original patent. The integration of these technologies enables a more efficient, personalized, and secure gene delivery system.
Alternative Embodiments and Variations
Alternative embodiments may include using different types of blockchain networks, incorporating additional AI algorithms for gene expression prediction, or integrating with other IoT devices for real-time monitoring. Variations may also include using different types of gene delivery compositions or targeting different cell types.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the gene therapy market, particularly in personalized medicine and targeted gene delivery. The system's ability to optimize gene delivery routes, track gene expression, and enable secure data management makes it an attractive solution for pharmaceutical companies, biotech firms, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/1709 |
| A | A61 | A61K31/7088 |
| A | A61 | A61K31/7115 |
| C | C12 | C12Y207/07048 |
| C | C12 | C12N2310/113 |
| C | C12 | C12N2710/10343 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Molecular Biology and Gene Delivery Systems, specifically focusing on RNA-based therapeutic compositions and advanced biotechnology integration, requiring advanced degrees in molecular biology, genetics, or bioengineering with expertise in gene therapy technologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced training in molecular biology, capable of understanding complex gene delivery mechanisms, familiar with viral replication systems, and knowledgeable about emerging technologies in biotechnology and computational approaches to genetic engineering
Obviousness Rationale
A person skilled in the art would recognize that integrating computational technologies with existing gene delivery compositions represents a natural progression in biotechnological innovation. The source patent's foundational work on self-replicating cell selective gene delivery provides a clear technological framework that can be readily augmented with emerging digital technologies. The combination of blockchain, machine learning, and IoT with gene delivery systems represents an obvious extension of known technological integration strategies in advanced biotechnology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,598 |
|---|---|
| Title | Self-replicating cell selective gene delivery compositions, methods, and uses thereof |
| Assignee(s) | University of South Florida |